PRODIGY: A Phase III Study of Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 Versus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer

Adjuvant chemotherapy after D2 gastrectomy is standard for resectable locally advanced gastric cancer (LAGC) in Asia. Based on positive findings for perioperative chemotherapy in European phase III studies, the phase III PRODIGY study (ClinicalTrials.gov identifier: NCT01515748) investigated whether...

Descripción completa

Detalles Bibliográficos
Autores principales: Kang, Yoon-Koo, Yook, Jeong Hwan, Park, Young-Kyu, Lee, Jong Seok, Kim, Young-Woo, Kim, Jin Young, Ryu, Min-Hee, Rha, Sun Young, Chung, Ik Joo, Kim, In-Ho, Oh, Sang Cheul, Park, Young Soo, Son, Taeil, Jung, Mi Ran, Heo, Mi Hwa, Kim, Hark Kyun, Park, ChoHyun, Yoo, Chang Hak, Choi, Jin-Hyuk, Zang, Dae Young, Jang, You Jin, Sul, Ji Young, Kim, Jong Gwang, Kim, Beom Su, Beom, Seung-Hoon, Cho, Sang Hee, Ryu, Seung Wan, Kook, Myeong-Cherl, Ryoo, Baek-Yeol, Kim, Hyun Ki, Yoo, Moon-Won, Lee, Nam Su, Lee, Sang Ho, Kim, Gyunji, Lee, YeonJu, Lee, Jee Hyun, Noh, Sung Hoon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2021
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8425847/
https://www.ncbi.nlm.nih.gov/pubmed/34133211
http://dx.doi.org/10.1200/JCO.20.02914

Ejemplares similares

Ejemplares similares